JPJ. Edward Puzas

J. Edward Puzas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


J. Edward Puzas has a total of 42 co-authors. Here are the top co-authors by number of shared publications:

  • Tzong-Jen Sheu

    Center for Musculoskeletal Research, University of Rochester, School of Medicine and Dentistry, Rochester, NY, USA

    6 shared publications
  • Jonathan D. Holz

    Department of Orthopaedics, Center for Musculoskeletal Research, University of Rochester, Rochester, New York 14642, USA

    5 shared publications
  • Eric E. Beier

    Center for Musculoskeletal Research; Department of Environmental Medicine, University of Rochester School of Medicine and Dentistry, Rochester, 14624; and

    4 shared publications
  • Michael J. Zuscik

    Colorado Program for Musculoskeletal Research, Department of Orthopedics University of Colorado Anschutz Medical Campus Aurora Colorado USA

    4 shared publications
  • Tzong‐Jen Sheu

    Center for Musculoskeletal Research University of Rochester, School of Medicine and Dentistry Rochester New York 14642

    3 shared publications
  • R N Rosier

    2 shared publications

Latest Publications

  • Open Access

    Sclerostin activity plays a key role in the negative effect of glucocorticoid signaling on osteoblast function in mice

    by Eric E Beier, Tzong-Jen Sheu, Emily A Resseguie, Masahiko Takahata, Hani A Awad, Deborah A Cory-Slechta, J Edward Puzas

    Stress during prenatal development is correlated with detrimental cognitive and behavioral outcomes in offspring. However, the long-term impact of prenatal stress (PS) and disrupted glucocorticoid signaling on bone mass and strength is not understood. In contrast, the detrimental effect of lead (Pb) on skeletal health is well documented. As stress and Pb act on common biological targets via glucocorticoid signaling pathways and co-occur in the environment, this study first sought to assess the combined effect of stress and Pb on bone quality in association with alterations in glucocorticoid signaling. Bone parameters were evaluated using microCT, histomorphometry, and strength determination in 8-month-old male mouse offspring subjected to PS on gestational days 16 and 17, lifetime Pb exposure (100 p.p.m. Pb in drinking water), or to both. Pb reduced trabecular bone mass and, when combined with PS, Pb unmasked an exaggerated decrement in bone mass and tensile strength. Next, to characterize a mechanism of glucocorticoid effect on bone, prednisolone was implanted subcutaneously (controlled-release pellet, 5 mg·kg−1 per day) in 5-month-old mice that decreased osteoblastic activity and increased sclerostin and leptin levels. Furthermore, the synthetic glucocorticoid dexamethasone alters the anabolic Wnt signaling pathway. The Wnt pathway inhibitor sclerostin has several glucocorticoid response elements, and dexamethasone administration to osteoblastic cells induces sclerostin expression. Dexamethasone treatment of isolated bone marrow cells decreased bone nodule formation, whereas removal of sclerostin protected against this decrement in mineralization. Collectively, these findings suggest that bone loss associated with steroid-induced osteoporosis is a consequence of sclerostin-mediated restriction of Wnt signaling, which may mechanistically facilitate glucocorticoid toxicity in bone.


  • Open Access

    Elevated Lifetime Lead Exposure Impedes Osteoclast Activity and Produces an Increase in Bone Mass in Adolescent Mice

    by Eric E. Beier, Jonathan D. Holz, Tzong-Jen Sheu, J. Edward Puzas

    The heavy metal lead (Pb) has a deleterious effect on skeletal health. Because bone mass is maintained through a balance of bone formation and resorption, it is important to understand the effect of Pb levels on osteoblastic and osteoclastic activity. Pb exposure is associated with low bone mass in animal models and human populations; however, the correlation between Pb dosing and corresponding bone mass has been poorly explored. Thus, mice were exposed to increasing Pb and at higher levels (500 ppm), there was unexpectedly an increase in femur-tibial bone mass by 3 months of age. This is contrary to several studies alluded to earlier. Increased bone volume was accompanied by a significant increase in cortical thickness of the femur and trabecular bone that extended beyond the epiphyseal area into the marrow cavity. Subsequent evaluations revealed an increase in osteoclast numbers with high Pb exposure, but a deficiency in osteoclastic activity. These findings were substantiated by observed increases in levels of the resorption-altering hormones calcitonin and estrogen. In addition we found that pro-osteoclastic nuclear factor-kappa beta (NF-κB) pathway activity was dose dependently elevated with Pb, both in vivo and in vitro. However, the ability of osteoclasts to absorb bone was depressed in the presence of Pb in media and within test bone wafers. These findings indicate that exposure to high Pb levels disrupts early life bone accrual that may involve a disruption of osteoclast activity. This study accentuates the dose dependent variation in Pb exposure and consequent effects on skeletal health.


  • Open Access

    Heavy Metal Ion Regulation of Gene Expression

    by Eric E. Beier, Tzong-Jen Sheu, Deborah Dang, Jonathan D. Holz, Resika Ubayawardena, Philip Babij, J. Edward Puzas


  • Open Access

    Inhibition of beta‐catenin signaling by Pb leads to incomplete fracture healing

    by Eric E. Beier, Tzong‐Jen Sheu, Taylor Buckley, Kiminori Yukata, Regis O'KEefe, Michael J. Zuscik, J. Edward Puzas

    There is strong evidence in the clinical literature to suggest that elevated lead (Pb) exposure impairs fracture healing. Since Pb has been demonstrated to inhibit bone formation, and Wnt signaling is an important anabolic pathway in chondrocyte maturation and endochondral ossification, we investigated the impact of Wnt therapy on Pb‐exposed mice undergoing bone repair in a mouse tibial fracture model. We established that tibial fracture calluses from Pb‐treated mice were smaller and contained less mineralized tissue than vehicle controls. This resulted in the persistence of immature cartilage in the callus and decreased β‐catenin levels. Reduction of β‐catenin protein was concurrent with systemic elevation of LRP5/6 antagonists DKK1 and sclerostin in Pb‐exposed mice throughout fracture healing. β‐catenin stimulation by the GSK3 inhibitor BIO reversed these molecular changes and restored the amount of mineralized callus. Overall, Pb is identified as a potent inhibitor of endochondral ossification in vivo with correlated effects on bone healing with noted deficits in β‐catenin signaling, suggesting the Wnt/β‐catenin as a pivotal pathway in the influence of Pb on fracture repair. © 2014 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 32:1397–1405, 2014.


  • Open Access

    Heavy Metal Lead Exposure, Osteoporotic-like Phenotype in an Animal Model, and Depression of Wnt Signaling

    by Eric E. Beier, Jason R. Maher, Tzong-Jen Sheu, Deborah A. Cory-Slechta, Andrew J. Berger, Michael J. Zuscik, J. Edward Puzas

    A peer-reviewed open access journal published by the National Institute of Environmental Health Sciences


  • Open Access

    Lead induces an osteoarthritis‐like phenotype in articular chondrocytes through disruption of TGF‐β signaling

    by Jonathan D. Holz, Eric Beier, Tzong‐Jen Sheu, Resika Ubayawardena, Meina Wang, Erik R. Sampson, Randy N. Rosier, Michael Zuscik, J. Edward Puzas

    Lead remains a significant environmental toxin, and we believe we may have identified a novel target of lead toxicity in articular chondrocytes. These cells are responsible for the maintenance of joint matrix, and do so under the regulation of TGF‐β signaling. As lead is concentrated in articular cartilage, we hypothesize that it can disrupt normal chondrocyte phenotype through suppression of TGF‐β signaling. These experiments examine the effects of lead exposure in vivo and in vitro at biologically relevant levels, from 1 nM to 10 µM on viability, collagen levels, matrix degrading enzyme activity, TGF‐β signaling, and articular surface morphology. Our results indicate that viability was unchanged at levels ≤100 µM Pb, but low and high level lead in vivo exposure resulted in fibrillation and degeneration of the articular surface. Lead treatment also decreased levels of type II collagen and increased type X collagen, in vivo and in vitro. Additionally, MMP13 activity increased in a dose‐dependent manner. Active caspase 3 and 8 were dose‐dependently elevated, and treatment with 10 µM Pb resulted in increases of 30% and 500%, respectively. Increasing lead treatment resulted in a corresponding reduction in TGF‐β reporter activity, with a 95% reduction at 10µM. Levels of phosphoSmad2 and 3 were suppressed in vitro and in vivo and lead dose‐dependently increased Smurf2. These changes closely parallel those seen in osteoarthritis. Over time this phenotypic shift could compromise maintenance of the joint matrix. © 2012 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 30:1760–1766, 2012


  • Open Access

    TRIP-1: A regulator of osteoblast function

    by Diana Metz-Estrella, Jennifer H Jonason, Tzong-Jen Sheu, Rachel M Mroczek-Johnston, J Edward Puzas

    Transforming growth factor β (TGFβ) receptor interacting protein‐1 (TRIP‐1) is an intracellular protein expressed in osteoblasts with high affinity for type 5b tartrate resistant acid phosphatase (TRAP). It is suggested that through this interaction, TRIP‐1 serves as a positive regulator of TGFβ signaling and osteoblast differentiation during bone remodeling. We show here that TRIP‐1 is abundant in osteoblasts in vivo and in vitro. TRIP‐1 mRNA and protein expression were increased at early stages and decreased at later stages during osteoblast differentiation, suggesting a predominant role during early maturation. To investigate a role during bone remodeling, primary osteoblasts were treated with different hormones and factors that are known to affect remodeling. TRIP‐1 levels were decreased with dexamethasone and increased with vitamin D3, dihydrotestosterone (DHT), TGFβ1, and bone morphogenic protein 2 (BMP‐2). Treatment with parathyroid hormone (PTH) and β‐estradiol did not affect TRIP‐1 levels. Transfected small interfering RNA (siRNA) against TRIP‐1 inhibited osteoblast differentiation as characterized by a decrease in alkaline phosphatase staining and enzyme activity, and decrease in the expression of collagen I, alkaline phosphatase, Runx2, osteopontin, and osteocalcin. The proliferation of osteoblasts was also affected by TRIP‐1 siRNA. This particular effect was defined by decreased cell number, marked reduction of cyclin D1, a 38% decrease of cells in S phase (p < 0.001) and a 97% increase of cells in the G2/M phase (p < 0.01) of the cell cycle. However, TRIP‐1 siRNA did not induce an effect in apoptosis. Using a TGFβ luciferase reporter we found that knocking down TRIP‐1 decreased the activation of TGFβ signaling by 40% percent (p < 0.001). In conclusion, our characterization of TRIP‐1 in osteoblasts provides the first evidence of its key role as a positive regulator of osteoblast function. © 2012 American Society for Bone and Mineral Research.


  • Orthopedic Uses of Teriparatide

    by Susan V. Bukata, J. Edward Puzas

    Teriparatide is a drug currently approved for treating patients with osteoporosis who are at high risk for future fracture. In the treatment of osteoporosis, teriparatide works as an anabolic agent stimulating bone formation throughout the skeleton by principally enhancing osteoblast-derived bone formation relative to osteoclast-derived bone resorption. The net effect is increased bone mass. For patients with a fracture, a similar process of increased bone formation is required transiently at the fracture site for repair. Teriparatide has been investigated in animal models and in patients as a potential agent to enhance fracture repair. In addition, evidence that teriparatide enhances chondrogenesis has generated interest in using the agent for articular cartilage repair. Research is currently underway to understand the effects teriparatide may have on mesenchymal stem cells, and on other effects that have been reported anecdotally in patients using the drug for osteoporosis care, including the healing of fracture nonunions and a decreased incidence of back pain. We review the current animal and human reports available on the uses of teriparatide in musculoskeletal diseases beyond osteoporosis.


  • Open Access

    Environmental Toxicants May Modulate Osteoblast Differentiation by a Mechanism Involving the Aryl Hydrocarbon Receptor

    by Elizabeth P Ryan, Jonathan D Holz, Mary Mulcahey, Tzong-Jen Sheu, Thomas A Gasiewicz, J Edward Puzas

    The AHR mediates many of the toxicological effects of aromatic hydrocarbons. We show that AHR expression in osteoblasts parallels the induction of early bone-specific genes involved in maturation. Th...